This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): injectable rBPI21, opebacan
Description: NEUPREX is an injectable formulation ofrBPI-21, a genetically engineered fragment of human bactericidal/permeability-increasing protein(BPI). BPI kills gram-negative bacteria, enhances the activity of antibiotics and neutralizes gram-negative endotoxin.
Endotoxin is a primary trigger of the inflammatory processes that lead to shock, multiorgan failure, and purpura fulminans in meningococcal sepsis. Bactericidal/permeability-increasing protein (BPI) is a natural protein, stored within the neutrophil granules, that binds to and neutralises the effects of endotoxin in vitro, in laboratory animals, and in humans.
Deal Structure: In January 2000, XOMA licensed certain rights to the NEUPREX formulation to Baxter Healthcare Corporation. Baxter will fund future development costs and XOMA will be entitled to certain milestone payments and a royalty on future product sales. Baxter has committed to development in multiple indications.
The partnership with Baxter terminated in July 2003.
In November of 2004, XOMA announced the licensing of its BPI product platform, including NEUPREX, to Zephyr. In July of 2005, XOMA announced its decision to terminate the license agreement with Zephyr due to Zephyr not meeting the financing requirements of the license agreement.
Partners: Baxter International Inc.
Additional information available to subscribers only: